Literature DB >> 35573931

First Pediatric Case of Autosomal Recessive Homozygotic Bestrophinopathy due to Homozygous Mutation c.187G>C p. in Two Brothers.

Stefan Bittmann1, Elisabeth Luchter1, Gloria Villalon1, Elena Moschuring-Alieva1, Lara Bittmann1, Anne Weissenstein1.   

Abstract

Entities:  

Year:  2022        PMID: 35573931      PMCID: PMC9076138          DOI: 10.14740/jocmr4709

Source DB:  PubMed          Journal:  J Clin Med Res        ISSN: 1918-3003


× No keyword cloud information.

To the Editor

Autosomal recessive bestrophinopathy (ARB) is associated with mutations of the bestrophin-1 (BEST1) gene. BEST1 is one of four related genes that influence integral membrane proteins, called BEST1-4 genes, and were classified into five different classes (class I-V) [1]. The BEST1 mutation spectrum underlying bestrophinopathies involves over 300 known mutations [1-6]. In BEST1 gene mutations, gain-of-function and loss-of-function mutations occur [1, 5, 7]. The prevalence of autosomal recessive pattern of BEST1 mutation is described as 1:1,000,000 [8]. To date, there is no effective treatment of bestrophinopathies [7]. Prognosis of the different BEST mutations and their clinical features are not clearly definable [1, 5, 7, 8]. The pathology focuses on why BEST1 mutations disturb calcium-activated chloride channel activity with the result of retinal degeneration [2, 5, 9-12]. BEST1 mutations are normally autosomal dominant, but sometimes autosomal recessive and therefore as recessive entity indicative for ARB [7]. This genetic condition leads to different diseases of retinal degenerative disorders. ARB is rarely diagnosed compared to BEST1-associated autosomal dominant juvenile vitelliform macular degeneration (VMD) (Best’s disease), which is not only due to its low prevalence (1:50,000), but also to the phenotypic differences to VMD [13-15]. Mutations in the BEST1 gene are causally associated with an increasing number of inherited ophthalmic diseases, which have collectively been termed “bestrophinopathies”. These have initially included inherited retinal degenerative diseases, one of the most common inherited macular diseases, ARB, and autosomal dominant vitreoretinochoroidopathy (ADVIRC), among others. However, BEST1 mutations have also been implicated in more complex ophthalmic diseases with anterior segment involvement, namely autosomal dominant microcornea, rod-cone dystrophy, early-onset cataract, posterior staphyloma (MRCS) syndrome. ARB normally shows first clinical expression in the first two decades of life, but a few patients show first visual disturbances in the fifth decade of life. Mostly patients present with a central visual loss with a visual acuity range from 20/200 to 20/25 and show a hyperopic state. Additional ocular disturbances include a lower axial length with glaucoma, amblyopia and anterior uveitis. Strabismus and color vision defects are also found. Choroidal neovascularization (CNV) could also be an infrequent sign. Leukokoria and esotropia have also been described in literature. In addition, phenotypical differences have been noted between unrelated patients harboring the same mutation and also within families, including age of onset and rate of disease progression. This phenotypic and allelic heterogeneity highlights a significant phenotypic overlap among BEST1-linked disorders, which poses significant diagnostic and prognostic challenges. The pleiotropic effects of BEST1 gene mutations have raised the hypothesis that other unknown factors may play a role in bestrophinopathies, including genetic modifiers, BEST1 protein interactors, and environmental components. A decreased electro-oculographic (EOG) Arden ratio (light peak/dark trough) is a hallmark of all bestrophinopathies. This clinical finding has allowed further understanding of the biologic role of BEST proteins in the human eye. We present the first pediatric case of a homozygous mutation c.187G>C p. in two brothers aged 6 and 16 years old. In the complete analysis of the BEST1 gene in the one boy, there was detection of homozygous mutation c.187G>C p. (Glu63Gln). Identical findings were noted in the clinically also affected brother. Both parents are from Kayseri, Turkey, and ophthalmologically healthy. The 75-year-old grandfather of the brothers has late manifestation of blindness since the age of 10, with onset of visual deterioration from the age of 45. The methodological analysis was DNA extraction from EDTA blood. PCR amplification of exon 3 of the BEST1 gene includes adjacent intron regions from generic DNA and subsequent analysis by double-stranded sequencing. The analysis and sequence alignment to the reference (ENST00000378043.9) was performed using the software “Sequence Pilot”. The databases dbSNP, ExAc, gnomAD, HGMD and Uni Prot, as well as the prediction programs Predict SNP, Poly Phen 2, SIFT, SNAP, MAPP, PhDSNP, Poly Phen 1 and panther were used for the evaluation of variants. This analysis failed to detect low-grade mosaics, larger delegations or duplications and rearrangements, and mutations outside the regions of the BEST1 gene examined. If a patient with a clinical picture of ARB has both parental alleles (gene copies) of BEST1 mutated, so-called bi-allelic mutation status, and there is no ocular symptomatology in the parents, the diagnosis of ARB is very likely [2-5]. The diagnosis should then be confirmed by a supplementary family analysis. The clinical expression of identical genetic disposition can be quite variable, probably due to secondary developments in the wake of the gene mutation, such as neovascularization, glaucoma, extent of the macula, amblyopia in strabismus and glaucoma at least partially suitable to treat ARB [2-5]. The mutation in BEST1 found in the two brothers does not seem to have been described yet in world literature. Therefore, prognostic recommendations of course and treatability for the two children are limited. If the presumed homozygosity for the putative pathogenic BEST1 mutation in the two brothers can be indirectly confirmed by family analysis, this would further confirm the diagnosis [2-5]. Furthermore, it can be assumed that the future children of the brothers will only be at increased risk for ARB if their future partners also happen to be conductors of a pathogenic BEST1 mutation. If the partner is not from the family, i.e., no partnership with blood relatives is entered into, this risk is very low. In conclusion, ARB is an extremely rare disease in childhood, especially in brothers. This is the first case of a new homozygous BEST mutation of two brothers with ARB in world literature to date.
  15 in total

Review 1.  Bestrophin 1 and retinal disease.

Authors:  Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Prog Retin Eye Res       Date:  2017-01-30       Impact factor: 21.198

2.  Mutation spectrum of the bestrophin-1 gene in a large Chinese cohort with bestrophinopathy.

Authors:  Feng-Juan Gao; Yu-He Qi; Fang-Yuan Hu; Dan-Dan Wang; Ping Xu; Jing-Li Guo; Jian-Kang Li; Yong-Jin Zhang; Wei Li; Fang Chen; Ge-Zhi Xu; Wei Liu; Qing Chang; Ji-Hong Wu
Journal:  Br J Ophthalmol       Date:  2019-09-13       Impact factor: 4.638

3.  Bestrophin 1 gene analysis and associated clinical findings in a Chinese patient with Best vitelliform macular dystrophy.

Authors:  Ying Lin; Tao Li; Hongbin Gao; Yu Lian; Chuan Chen; Yi Zhu; Yonghao Li; Bingqian Liu; Wenli Zhou; Hongye Jiang; Xialin Liu; Xiujuan Zhao; Xiaoling Liang; Chenjin Jin; Xinhua Huang; Lin Lu
Journal:  Mol Med Rep       Date:  2017-08-04       Impact factor: 2.952

4.  BEST1 protein stability and degradation pathways differ between autosomal dominant Best disease and autosomal recessive bestrophinopathy accounting for the distinct retinal phenotypes.

Authors:  Andrea Milenkovic; Vladimir M Milenkovic; Christian H Wetzel; Bernhard H F Weber
Journal:  Hum Mol Genet       Date:  2018-05-01       Impact factor: 6.150

5.  Mitochondrial oxidative stress in the retinal pigment epithelium (RPE) led to metabolic dysfunction in both the RPE and retinal photoreceptors.

Authors:  Emily E Brown; Alexander J DeWeerd; Cristhian J Ildefonso; Alfred S Lewin; John D Ash
Journal:  Redox Biol       Date:  2019-04-20       Impact factor: 11.799

6.  Clinical Heterogeneity in Autosomal Recessive Bestrophinopathy with Biallelic Mutations in the BEST1 Gene.

Authors:  Karsten Hufendiek; Katerina Hufendiek; Herbert Jägle; Heidi Stöhr; Marius Book; Georg Spital; Günay Rustambayova; Carsten Framme; Bernhard H F Weber; Agnes B Renner; Ulrich Kellner
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

7.  Novel BEST1 mutation in autosomal recessive bestrophinopathy in Japanese siblings.

Authors:  Rika Yamada; Rina Takagi; Sadahiko Iwamoto; Shoichi Shimada; Akihiro Kakehashi
Journal:  Taiwan J Ophthalmol       Date:  2021-01-07

8.  Autosomal Recessive Bestrophinopathy: Clinical Features, Natural History, and Genetic Findings in Preparation for Clinical Trials.

Authors:  Giuseppe Casalino; Kamron N Khan; Monica Armengol; Genevieve Wright; Nikolas Pontikos; Michalis Georgiou; Andrew R Webster; Anthony G Robson; Parampal S Grewal; Michel Michaelides
Journal:  Ophthalmology       Date:  2020-10-08       Impact factor: 12.079

9.  Evaluating BEST1 mutations in pluripotent stem cell-derived retinal pigment epithelial cells.

Authors:  Alec Kittredge; Yu Zhang; Tingting Yang
Journal:  Methods Enzymol       Date:  2021-02-27       Impact factor: 1.600

10.  Genetic variations in Bestrophin‑1 and associated clinical findings in two Chinese patients with juvenile‑onset and adult‑onset best vitelliform macular dystrophy.

Authors:  Ying Lin; Tao Li; Chenghong Ma; Hongbin Gao; Chuan Chen; Yi Zhu; Bingqian Liu; Yu Lian; Ying Huang; Haichun Li; Qingxiu Wu; Xiaoling Liang; Chenjin Jin; Xinhua Huang; Jianhua Ye; Lin Lu
Journal:  Mol Med Rep       Date:  2017-10-27       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.